List view / Grid view
Global mergers and acquisitions (M&A) activity last year was expected to decline from 2019 levels, mainly due to the COVID-19 pandemic and resulting uncertainty around the global economy, trade tensions between the US and China, and the presidential election in the US. However, James Baillieu from Bird & Bird reveals…
While the sera were able to neutralise SARS-CoV-2 viruses expressing the B.1.351-spike mutations in vitro, the neutralisation was almost two thirds weaker than for an early strain.
Pfizer and BioNTech have agreed to supply the European Union with 200 million additional doses of COMIRNATY in 2021, making the total 500 million doses.
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine-300x278.jpg)
![Male Thai child receiving oral polio vaccine from healthcare worker [Credit: frank60 / Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Oral-vaccine.jpg)
The market is expected to grow at a 6.7 percent CAGR, driven by the increasing prevalence of cancer and cardiovascular diseases, as well as growing interest in biologics.
Research suggests at least a fifth of the US population are resistant to receiving a COVID-19 vaccine, reports suggest this could be due to disinformation and safety concerns.
Research suggests that despite a COVID-19 slump, the anti-Parkinson’s drugs market will recover due to rising numbers of Parkinson’s diagnoses and increasing investment in R&D.
In this article we discuss how the problems associated with glass vial packaging may disrupt COVID-19 vaccine distribution and explore some of the latest innovations to overcome it.
The UK Government has given £7 million of funding for a clinical trial which will investigate whether patients can be given different COVID-19 vaccines for each dose.
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
Pharmacist Ezeokafor Ifeoma Charity explores to what extent COVID-19 has prompted the growth of the pharmaceutical industry.
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
In a Phase I/II trial, 81 percent of paediatric patients with relapsed or refractory, systemic anaplastic large cell lymphoma achieved complete remission with crizotinib (Xalkori).
Over a six year period, the Pfizer-BioNTech COVID-19 vaccine is expected to lead inoculation sales, generating $30 billion.
Despite the stringent storage conditions required for Pfizer and BioNTech’s COVID-19 vaccine, the need for a return to normal life has levelled the playing field for all candidate prophylactics against SARS-CoV-2.
